Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia

Lignende værker

• Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
  af: Jasra, Sakshi, et al.
  Udgivet: (2021)
• Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification
  af: Rajvi Gor, et al.
  Udgivet: (2025-08-01)
• Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
  af: Alex Bataller, et al.
  Udgivet: (2025-03-01)
• Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia
  af: Venugopal, Sangeetha, et al.
  Udgivet: (2021)
• Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
  af: Saleh, Mostafa F. M., et al.
  Udgivet: (2017)